Curaleaf Sets December 1 Tender Deadline, Escalates Hostile Bid for Aurora
CURLF sits 88% above its 52-week low of $5.4 on light trading volume (0.3× avg).
Summary
Curaleaf published a shareholder brochure setting a December 1, 2026 tender deadline for its hostile bid for Aurora Cannabis, revealing new data showing Aurora raised US$398M in dilutive equity and saw adjusted EBITDA decline 78%.
Key Events · M&A and Partnerships · CURLF
-
Tender Deadline Set for December 1, 2026
Curaleaf's brochure explicitly states Aurora shareholders must tender their shares before December 1, 2026, creating a concrete deadline for the hostile takeover bid.
-
Aurora Raised US$398M Through Dilutive Equity
Curaleaf alleges Aurora management raised US$398M through dilutive equity issuances, arguing this has made Aurora shares less valuable.
-
Aurora Financial Deterioration Detailed
Over the last four quarters, Aurora's net revenue declined 14% and adjusted EBITDA declined 78%, with operating cash flow negative US$18M (LTM, adjusted for lease principal payments).
-
Auditor Concerns Over Inventory Controls
Curaleaf states Aurora's own auditors question management's inventory controls in place, adding a governance concern to the bid narrative.
Analysis · CURLF · Life Sciences
Curaleaf is escalating its hostile takeover of Aurora Cannabis by publishing a shareholder brochure that sets a December 1, 2026 tender deadline and reveals new financial deterioration data about Aurora. The brochure claims Aurora raised US$398M through dilutive equity issuances, saw net revenue decline 14% and adjusted EBITDA decline 78% over the last four quarters, and that Aurora's own auditors question management's inventory controls. This is a material escalation of the bid — a concrete deadline creates urgency for Aurora shareholders, and the new financial data is designed to pressure Aurora's board to engage. The offer remains US$4.00 per share (0.3463 Curaleaf shares plus US$0.75 cash), a 45% premium to Aurora's 30-day VWAP on August 10, 2026.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 34.9% of the 1159 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $10.15 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.